Mode of action of orlistat

International Journal of Obesity

Volumn 21, Issue SUPPL. 3, 1997, Pages

  Guerciolini, R ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Drug interaction; Faecal fat; Fat absorption; Lipases; Orlistat

Indexed keywords

AMYLASE; CHYMOTRYPSIN; DIGOXIN; ELECTROLYTE; FATTY ACID; FECES LIPID; GLIBENCLAMIDE; MINERAL; MONOACYLGLYCEROL; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PHOSPHOLIPASE; PRAVASTATIN; SERINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TRYPSIN; WARFARIN;

BILE COMPOSITION; CONFERENCE PAPER; COVALENT BOND; DIGESTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; ELECTROLYTE BALANCE; ENZYME ACTIVE SITE; ENZYME INHIBITION; FAT INTAKE; FECES; GALLBLADDER MOTILITY; HUMAN; HYDROLYSIS; LIPID ABSORPTION; LOW CALORY DIET; MINERAL BALANCE; OBESITY; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; STOMACH EMPTYING; STOMACH PH; STONE FORMATION;

AREA UNDER CURVE; DIGESTION; ENZYME INHIBITORS; HUMANS; INTESTINAL ABSORPTION; LACTONES; LIPASE;

EID: 0030952712     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Verger, R. Enzyme kinetics of lipolysis. In: Methods of Enzymology. Vol 64. Academic Press: New York, 1980, pp 340-392.
2. Shiau YK. Lipid digestion and absorption. In: Johnson LR (ed). Physiology of the Gastrointestinal Tract. 2nd edn. Raven Press: New York, 1987, pp 1527-1556.
3. Block G, Rosenberger WF, Patterson BH. Calories, fat and cholesterol: intake patterns in the US population by race, sex and age. Am J Public Health 1988; 78: 1150-1155.
4. Meyer JH, Mayer EA, Jehn D, Gu Y, Fink AS, Fried M. Gastric processing and emptying of fat. Gastroenterology 1986; 90: 1176-1187.
5. Gargouri Y, Pieroni G, Riviere C, Sauniere JF, Lowe PA, Sarda L, Verger R. Kinetic assay of human gastric lipase on short and long-chain triacylglycerol emulsions. Gastroenterology 1986; 91: 919-925.
6. Borgstöm B, Dahlqvist A, Lundh G, Sjövall J. Studies in intestinal digestion and absorption in the human. J Clin Invest 1957; 36: 1521-1536.
7. Staggers JE, Hernell O, Stafford RJ, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 1990; 29: 2028-2040.
8. Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 1990; 29: 2041-2056.
9. Wang CS, Hartsuck JA. Bile salt-activated lipase. A multiple function lipolytic enzyme. Biochem Biophys Acta 1993; 1166: 1-19.
10. Lindström MB, Sternby B, Borgström B. Concerted action of human carboxyl ester lipase and pancreatic lipase during lipid digestion in vitro: importance of the physicochemical state of the substrate. Biochem Biophys Acta 1988; 959: 178-184.
11. Gaskin KJ, Durie PR, Lee L, Hill R, Forstner GG. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency. Gastroenterology 1984; 86: 1-7.
12. Ghisan FK, Moran JR, Durie PR, Greene HL. Isolated congenital lipase-colipase deficiency. Gastroenterology 1984; 86: 1580-1582.
13. Ligumsky M, Granot E, Branski D, Stankiewicz H, Goldstein R. Isolated lipase and colipase deficiency in two brothers. Gut 1990; 31: 1416-1418.
14. Derewenda ZS, Sharp AM. News from the interface: the molecular structure of triacylglyceride lipases. Trends Biochem Sci 1993; 18: 20-25.
15. Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiotics 1987; 40: 1081-1085.
16. Hochuli E, Kupfer E, Maurer R, Meister W, Mercadel Y, Schmidt K. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J Antibiotics 1987; 40: 1086-1091.
17. Kafil J, Manius G, Babinski E, Bhattacharyya P, Calabrese F, Manalili F, Shumway M. Ro 18-0647/002 drug substance: physical and chemical characterization, quality control IND specifications and directions for testing, methods validation, and stability. Research Report N-124'891, January 3, 1989.
18. Borgström B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochem Biophys Acta 1988; 962: 308-316.
19. Lüthi-Peng Q, Winkler FK. Large spectral changes accompany the conformational transition of human pancreatic lipase induced by acylation with the inhibitor tetrahydrolipstatin. Eur J Biochem 1992; 205: 383-390.
20. Cudrey C, van Tilebeurgh H, Gargouri Y, Verger R. Inactivation of pancreatic lipases by amphiphilic reagents (5-(dodecyldithio)-2-nitrobenzoic acid and tetrahydrolipstatin. Dependence upon partitioning between micellar and oil phases. Biochemistry 1993; 32: 13800-13808.
21. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988; 256: 357-361.
22. Ransac S, Gargouri Y, Morau H, Verger R. Inactivation of pancreatic and gastric lipases by tetrahydrolipstatin and alkyldithio-5-(2-nitrobenzoic acid). A kinetic study with 1,2-didecanoyl-sn-glycerol monolayers. Eur J Biochem 1991; 202: 395-400.
23. Stalder H, Schneider PR, Oesterhelt G. Tetrahydrolipstatin: thermal and hydrolytic degradation. Helv Chim Acta 1990; 73: 1022-1036.
24. Gargouri Y, Morau H, Verger R. Gastric lipases: biochemical and physiological studies. Biochem Biophys Acta 1989; 1006: 255-271.
25. Reue K, Zambax J, Wong H, Lee G, Leete TH, Ronk M, Shively JE, Sternby B, Borgström B, Ameis D, Schotz MC. cDNA cloning of carboxyl ester lipase from human pancreas reveals an unique proline-rich repeat unit. J Lipid Res 1991; 32: 267-276.
26. Holm C, Kirchgessner TG, Svenson KL, Fredrikson G, Nilsson S, Miller CG, Shively JE, Heinzmann C, Sparkes RS, Mohandas T, Lusis AJ, Schotz MC. Hormone-sensitive lipase: sequence, expression, and chromosomal localization to 19 cent-q 13.3. Science 1988; 241: 1503-1506.
27. Winkler FK, D'Arcy A, Hunziker W. Structure of human pancreatic lipase. Nature 1990; 343: 771-774.
28. Brady L, Brzozowski AM, Derewanda ZS, Dodson E, Dodson G, Tolley S, Turkenburg JP, Christiansen L, Huge-Jensen B, Norskov L, Thim L, Menge U. A serine protease triad forms the catalytic centre of a triacylglycerol lipase. Nature 1990; 343: 767-770.
29. Schrag JD, Li Y, Wu S, Cygler M. Ser-His-Glu triad forms the catalytic site of the lipase from Geotrichum candidum. Nature 1991; 351: 761-764.
30. Lowe ME. The catalytic site residues and interfacial binding of human pancreatic lipase. J Biol Chem 1992; 267: 17069-17073.
31. Van Tilebeurgh H, Egloff MP, Martinez C, Rugani N, Verger R, Cambillau C. Structure of pancreatic lipase-procolipase complex. Nature 1992; 359: 159-162.
32. Van Tilebeurgh H, Egloff MP, Martinez C, Rugani N, Verger R, Cambillau C. Interfacial activation of the lipase-procolipase complex by mixed micelles revealed by X-ray crystallography. Nature 1993; 362: 814-820.
33. Inkler F, Gubernator K. Structure and mechanism of human pancreatic lipase. In: Woolley P (ed). Lipases - Their Biochemistry, Structure and Application. Cambridge University Press: Cambridge, 1993.
34. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-85.
35. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995; 35: 1103-1108.
36. Melia AT, Zhi J, Koss-Twardy SG, Min BH, Smith BL, Freundlich NL, Arora S, Passe SM. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995; 35: 840-843.
37. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996; 36(7): 654-658.
38. Zhi J, Melia AT, Guerciolini R, Koss-Twardy SG, Passe SM, Rakhit A, Sadowski JA. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J. Clin Pharmacol 1996; 36(7): 659-666.
39. Zhi J, Melia AT, Koss-Twardy SG, Min B, Guerciolini R, Freundlich NL, Milla G, Patel IH. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995; 35(5): 521-525.
40. Weber C, Tam YK, Schmidtke-Schrezenmeier, Jonkman JHG, van Brummelen P. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 87-90.
41. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996; 36: 352-355.
42. Hartmann D, Güzelhan C, Zuiderwijk PBM, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50: 421-424.